10/26/2026
Everything you were told about HRT may have changed.
For years, many women have approached menopausal hormone therapy with fear because of warnings surrounding breast cancer, cardiovascular disease, and dementia.
But the conversation is changing.
In February 2026, the FDA approved labeling changes for several menopausal hormone therapy products that removed risk statements related to cardiovascular disease, breast cancer, and probable dementia from the boxed warning, the FDA’s most prominent safety warning.
Why?
The FDA reevaluated the evidence, including important limitations in how older research was applied to women beginning hormone therapy around the time of menopause.
But this does not mean HRT is risk-free or appropriate for every woman.
Your age, symptoms, medical history, time since menopause, type of hormone therapy, and individual risk factors all matter.
The goal isn’t to convince every woman to take hormones.
It’s to move beyond fear and have an informed, individualized conversation about the potential benefits, risks, and alternatives.
Menopause care is evolving.
Your care should be personal.
Ready to understand your options?
DM “HRT” or schedule a consultation with NJ Alpha Health.
OPTIMIZE | RESTORE | PERFORM
Educational information only. Hormone therapy has potential benefits, risks, and contraindications and should be discussed with a qualified healthcare professional.
MenopauseHealth WomensHealth HormoneHealth HealthyAging NewJersey